Teladoc Health Reports Fourth-Quarter and Full-Year 2019 Results

Go back to Teladoc Health Reports Fourth-Quarter and Full-Year 2019 Results

Teladoc (TDOC) PT Raised to $150 at Cowen

February 27, 2020 6:30 AM EST

Cowen analyst Charles Rhyee raised the price target on Teladoc (NYSE: TDOC) to $150.00 (from $100.00) while maintaining an Outperform rating.

The analyst commented, "What's not to like? TDOC's 4Q19 results and 2020 guidance were both better than expected, and we see several potential near-term... More

Teladoc (TDOC) PT Raised to $140 at RBC Capital

February 27, 2020 6:20 AM EST

RBC Capital analyst Sean Dodge raised the price target on Teladoc (NYSE: TDOC) to $140.00 (from $110.00) while maintaining an Outperform rating.

The analyst commented, "Results were better than expected across all metrics. Most notably, mgmts 2020 revenue guide implies 27% growth at MP, topping the 24-25%... More